New 'abuse-deterrent painkiller' from Canton company approved by FDA

There may be no such thing as a truly abuse-deterrent opiate. But a Canton drug firm just got approval for an opioid painkiller that was shown in two recent studies to do a better job than what’s currently available. Collegium Pharmaceuticals (Nasdaq: COLL) shares rose nearly 13 percent in after-hours trading Tuesday after announcing FDA approval of its drug, Xtampza ER. The twice-a-day oxycodone drug, which the company plans to launch in coming months, relies on a formulation that encapsulates…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news